Humacyte Inc (HUMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $155.12M
Last updated: Nov 17, 2026 at 4:28 PM ET
Humacyte Inc (HUMA) Statistics
Humacyte (HUMA) has a market cap of $155.12M and an enterprise value of $156.47M. It kept -3955.05% of revenue as net income over the last 12 months. Its share count is up 75.47% from a year earlier.
Total Valuation
Enterprise value is 0.87% above the market cap, as debt exceeds cash.
| Market Cap | $155.12M |
|---|---|
| Enterprise Value | $156.47M |
| Latest price (Nov 17, 2026) | $0.50 |
Key Dates
The next earnings report is expected on Mar 25, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 25, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 58.1x and 7.7x. Its year-end P/S ranged from 27.3x to 138.9x from 2022 to 2025.
| P/S Ratio | 58.1x |
|---|---|
| Forward P/S | 38.9x |
| P/B Ratio | 7.7x |
Price Statistics
The stock is down 59.27% over 52 weeks and trades 2.04% above its 50-day average.
| Beta (1Y) | 2.67 |
|---|---|
| 52-Week Change | -59.27% |
| 1-Month Change | +24.91% |
| 3-Month Change | -31.83% |
| 6-Month Change | -39.29% |
| 5-Year Change | -95.48% |
| Total Return (1Y) | -59.27% |
| Total Return (3Y CAGR) | -41.63% |
| Total Return (5Y CAGR) | -46.58% |
| Max Drawdown (1Y) | -76.23% |
| Max Drawdown (3Y) | -96.26% |
| Sharpe Ratio (1Y) | -0.78 |
| Correlation with SPY (1Y) | 0.33 |
| 50-Day Average | $0.49 |
| 200-Day Average | $0.77 |
| 52-Week Range | $0.34 to $1.52 |
| RSI (14 Days) | 51.5 |
| Average Volume (20 Days) | 4.76M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.34x current liabilities, and total debt is 3.65x shareholder equity.
| Current Ratio | 3.34x |
|---|---|
| Quick Ratio | 3.11x |
| Debt / Equity | 3.65x |
| Interest Coverage | -1.99x |
Returns and Efficiency
Return on invested capital is -60.48% over the last 12 months, against a 5-year average of 47.26%.
| Return on Equity (ROE) | -524.60% |
|---|---|
| Return on Assets (ROA) | -75.47% |
| Return on Invested Capital (ROIC) | -60.48% |
| Return on Capital Employed (ROCE) | -63.75% |
| ROA (5Y Average) | -48.89% |
| ROIC (5Y Average) | 47.26% |
| Asset Turnover | 0.02x |
| Inventory Turnover | 2.14x |
| Receivables Turnover | 4.20x |
| Cash Conversion Cycle | 163 days |
Scores
HUMA has an Altman Z-Score of -9.22, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -9.22 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $2.40M over the last 12 months is down 72.77% from the 12 months before.
| Revenue | $2.40M |
|---|---|
| Revenue Growth (YoY) | -72.77% |
| Gross Profit | -$11.08M |
| Operating Income | -$110.29M |
| Pretax Income | -$94.76M |
| Net Income | -$94.76M |
| EBITDA | -$56.28M |
| EBIT | -$64.26M |
| Reported EPS (TTM) | -$0.51 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 14.38% of the $125.57M in total assets.
| Cash and Equivalents | $64.52M |
|---|---|
| Total Debt | $65.87M |
| Net Debt | $1.35M |
| Net Debt Per Share | $0.00 |
| Working Capital | $57.92M |
| Shareholder Equity | $18.06M |
| Book Value Per Share | $0.07 |
| Total Assets | $125.57M |
| Total Liabilities | $107.51M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$88.26M |
|---|---|
| FCF Per Share | -$0.32 |
| Depreciation and Amortization | $7.98M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -4602.92%.
| Gross Margin | -462.60% |
|---|---|
| Operating Margin | -4602.92% |
| Pretax Margin | -3955.05% |
| Net Margin | -3955.05% |
| EBITDA Margin | -2348.87% |
| EBIT Margin | -2682.10% |
Growth
Revenue grew 9.20% a year over 3 years.
| Revenue Growth (3Y CAGR) | +9.20% |
|---|---|
| Revenue Growth (5Y CAGR) | +6.45% |
| Book Value Per Share Growth (2Y CAGR) | -61.23% |
| Tangible Book Per Share Growth (2Y CAGR) | -61.23% |
Dividends and Yields
HUMA does not pay a dividend.
| Buyback Yield | -95.81% |
|---|---|
| Shareholder Yield | -95.81% |
Peer Position
Against 4 similar companies, HUMA has the highest P/S and the 3rd highest ROIC.
P/S RatioPeer median 2.1x
ROICPeer median -60.00%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 58.1x vs 2.1x median |
|---|---|
| ROIC | -60.48% vs -60.00% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -72.77% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 239.15% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +239.15% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About HUMA
What is HUMA's market cap?
Humacyte has a market cap of $155.12M. Its enterprise value, which adds debt and subtracts cash, is $156.47M.
How many shares of HUMA are outstanding?
Humacyte has 277.80M shares outstanding. The count is up 75.47% from a year earlier.
Does HUMA pay a dividend?
No. Humacyte does not pay a dividend.
How much debt does HUMA have?
Humacyte has $65.87M of total debt and $64.52M of cash and equivalents, a net debt position of $1.35M.
HUMA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors